Feb. 20, 2020—Thermo Fisher Scientific and NanoPin Technologies have entered into a collaborative relationship to advance blood-based infectious disease detection technology through the development of highly sensitive liquid chromatography-mass spectrometry–based workflows.
Through the detection of disease-related antigens directly from patient blood samples, NanoPin’s diagnostic platform using Thermo Fisher’s LC-MS technology will lead to the development of sensitive clinical assays for infectious disease, which aim to reduce time to results, determine infection stage, and monitor patient response to prescribed treatment.
“The current diagnostic solutions available for the detection and monitoring of infectious disease are not sufficient because they limit patient outcomes and the global management of such ailments,” Thomas Tombler, PhD, chief executive officer of NanoPin, said in a press release. “Through our agreement with Thermo Fisher, our unique diagnostic platform has the potential to change how infectious diseases, such as tuberculosis, are detected, treated, and controlled by solving the unmet needs of health care providers managing patient care throughout the world.”